CBD may help clear toxic protein buildup in neurodegenerative diseases

CBD has been shown in preclinical models to reduce oxidative stress, neuroinflammation, and protein misfolding across multiple neurodegenerative disease models. The review argues CBD may act on the proteostasis network, the cellular system responsible for maintaining proper protein folding and clearing aggregates.

Narrative review synthesizing preclinical and clinical evidence on CBD's effects on protein homeostasis pathways in neurodegenerative diseases including Alzheimer's, Parkinson's, Huntington's, ALS, and multiple sclerosis.

Neurodegenerative diseases share a common feature: buildup of misfolded proteins. If CBD can engage the cellular machinery that clears these aggregates, it could represent a disease-modifying approach rather than just symptom management.

Most current treatments for neurodegenerative diseases manage symptoms without addressing the underlying protein aggregation. CBD's proposed multi-target action on the proteostasis network could open a new therapeutic window, though human clinical validation remains limited.

Mostly based on preclinical (animal and cell) models. Human clinical evidence for CBD's protein-clearing effects is limited. Narrative review without systematic methodology. The proteostasis mechanism remains largely theoretical.